MedTrace Logo

Carfilzomib/Cyclophosphamide/Dexamethasone with Maintenance Carfilzomib in Multiple Myeloma

NCT02315716 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 281

Last updated 2024-12-06

No results posted yet for this study

Summary

The Cardamon trial is a phase 2 trial using the standard chemotherapy drugs cyclophosphamide and dexamethasone in combination with a new drug called Carfilzomib in patients with multiple myeloma.

Conditions

Interventions

PROCEDURE

Autologous Stem Cell Transplant (ASCT)

Randomisation to melphalan conditioned autologous stem cell transplant

DRUG

Consolidation with 4 cycles of CarCyDex

Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • University College, London

    lead OTHER

Principal Investigators

  • Kwee Yong · University College, London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-16
Primary Completion
2019-11-30
Completion
2029-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02315716 on ClinicalTrials.gov